The global nuclear medicine equipment market is expected to experience steady growth, expanding from $2.3 billion in 2022 to $3.4 billion by 2032, with a CAGR of 4.1 percent. The market is driven by factors such as the increasing prevalence of chronic diseases, the aging population, and the rising demand for customized drugs. Technological advancements like the development of radiotracers and data-integrated imaging systems also contribute to market growth. Leading players in the market are focusing on new product introductions to enhance their market share. Recent developments include Curium's acquisition of IASON and Lantheus' FDA approval for PYLARIFY injectable. Key players in the market include Philips Healthcare, GE Healthcare, and Siemens Healthineers AG.
Fri, 11 Aug 2023 10:02:23 GMT | PharmiWeb.com